PDCD1 and lung cancer: [1, 2] Inhibition of immune checkpoints such as Programmed cell Death protein 1 (PD-1) and Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) increase immune recognition in melanoma, lung cancer, and some lymphomas.